Ely Benaim - 06 Jan 2023 Form 4 Insider Report for NovoCure Ltd (NVCR)

Role
Chief Medical Officer
Signature
/s/ Steven Robbins Attorney in Fact for Ely Benaim
Issuer symbol
NVCR
Transactions as of
06 Jan 2023
Net transactions value
+$6,106
Form type
4
Filing time
10 Jan 2023, 15:14:46 UTC
Previous filing
04 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVCR Ordinary Shares Award $6,106 +98 +0.34% $62.30 28,770 06 Jan 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2022 through December 30, 2022. This transaction is also exempt under Rule 16b-3(c).
F2 In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2022.